Reevaluating HER2-null breast cancer using an enhanced HER2 immunohistochemistry protocol
- 13 May 2025
- journal article
- research article
- Published by Springer Nature in Breast Cancer
- Vol. 32 (4) , 874-880
Abstract
Human epidermal growth factor receptor 2 (HER2) status is crucial for the classification of breast cancer and the selection of its treatment. Although HER2-low breast cancer is a recognized therapeutic subgroup, the classification of HER2 immunohistochemistry (IHC) 0 remains unclear. We reassessed 58 HER2-null breast cancer cases using an enhanced HER2 IHC protocol and the VENTANA OptiView detection system. HER2 expression was evaluated based on membrane positivity rate (%) and staining intensity. Microscopic assessment was performed to determine the percentage of HER2-positive tumor cells. Digital image analysis was used to quantify staining intensity. Detectable membrane HER2 positivity was observed in all tumors previously classified as HER2-null; the positivity rates ranged from 0.33% to 90% and the staining intensity indicated both inter- and intratumoral heterogeneity. These findings suggest that enhanced HER2 IHC protocols can improve detection sensitivity. This approach may help to refine HER2 classification and optimize patient selection for HER2-targeted therapies. Further research is needed to determine the clinical significance of HER2 expression detected using enhanced protocols.Keywords
All Related Versions
This publication has 13 references indexed in Scilit:
- Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast CancerNew England Journal of Medicine, 2024
- Current status and challenges in HER2 IHC assessment: scoring survey results in JapanBreast Cancer Research and Treatment, 2024
- Quantitative comparison of immunohistochemical HER2‐low detection in an interlaboratory studyHistopathology, 2024
- Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: recommendations from the Japanese Breast Cancer Society Clinical Practice GuidelinesBreast Cancer, 2024
- Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patientsBreast Cancer Research and Treatment, 2023
- Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trialNature Medicine, 2023
- Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast CancerNew England Journal of Medicine, 2022
- Evolution of HER2-low expression from primary to recurrent breast cancernpj Breast Cancer, 2021
- HER2-Low Breast Cancer: Pathological and Clinical LandscapeJournal of Clinical Oncology, 2020
- Fiji: an open-source platform for biological-image analysisNature Methods, 2012